Lixte Biotechnology relieved of $3.1M funding obligation for Phase 2 sarcoma study

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Amendment No. 1 to clinical trial agreement with GEIS relieves Lixte of approx $3,095,000 obligation for randomized Phase 2 portion.
Phase 1b recruitment completed in Q3 2024; initial toxicity and preliminary efficacy data expected Q4 2025.
Study overall expected to be completed and report prepared by Dec 31, 2026.
Lixte's lead compound LB-100 studied with doxorubicin for advanced soft tissue sarcomas.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.